

# **GNYHA PSYCKES Quality Collaborative**

Evelyn Wong MD

Maimonides Medical Center

# Team Members

Andrew Kolodny MD, Chairman

Evelyn Wong MD, PSYCKES Team Leader

Kishor Malavade MD, Vice Chairman, Acute Care Services

Eli Blitz, Assistant Vice President, Psychiatry

Joseph Carmody MD, Associate Director of Residency Training

Rina Evans RPh, Clinical Pharmacist

Kenneth Harris MD, Medical Director, CMHC Primary Care

Tatyana Poblaguev MD, Director, Adult Ambulatory Psychiatry


Jimmy Wu, System Programmer

Aysha Siddique, Performance Improvement Specialist

Susan Goldberg RN, AVP Organizational Performance

# PSYCKES initially identified 85 Medicaid patients receiving high-risk medications

Maimonides Medical Center  
PSYCKES Project  
Breakdown of Anti-Psychotic Prescribing



■ Chlorpromazine

■ Olanzapine

■ Quetiapine

■ Thioridazine

# How has PSYCKES driven change?

- Resident education
- One-on-one case reviews & Clinical Reviews
- Metabolic Screening process
- EMR prompts



# Resident Education

- Initial introduction at orientation
- Ongoing education with new process developments



# Clinical Reviews

- 100% of initial PSYCKES population was reviewed in February 2011
  - Reassessment to be performed annually

# Screening for Metabolic Syndrome

- Modified American Diabetes Association guidelines for *all* patients receiving anti-psychotic medications regardless of their PSYCKES status

	Baseline	4 Weeks	8 Weeks	12 Weeks	Quarterly	Annually
Personal/Family	X					X
Weight (BMI)	X	X	X	X	X	X
Waist circumference	X	X	X	X	X	X
Blood pressure	X	X	X	X	X	X
HbA1c	X			X	X	X
Fasting lipid profile	X	X	X	X	X	X
Fasting glucose	X	X	X	X	X	X

# Prompts for Prescribers

- Whenever Seroquel is ordered in Electronic Medical Record the associated risks are displayed. The prescriber is prompted to select an indication and choose an alternative medication if possible.

QUetiapine - TESTPATIENT, PATIENTLAB

Order: QUetiapine Order ID: 001532SCH

Requested By: Louie, Dennis Template Name: QUetiapine 200mg Tablet

Messages: This Medication is associated with serious side effects including metabolic syndrome and diabetes. Please consider using alternative.

Start Date: Sep-26-2011 Start Time: Routine

Equivalent To: SEROquel

Indication For Use: \*

- Psychosis
- Mood Disorder
- Agitation
- Sleep - This indication has not been approved by our P-T Committee
- Anxiety - This indication has not been approved by our P-T Committee

Dose: 200 Unit of Measure: mg Drug Form: Tablet Patient's Own Medication:

(Weight type: WEIGHT)

Height (cm)	Weight (kg)	BSA
172.7	88	2.02
Apr-26-2011 09:00		Jun-06-2011 08:00

Route: \* Frequency: \* Patient May Self Administer:

Relevant Results

PRN  PRN Reason: Use Waking Hours Only:

Stop After (Duration): Clear

(Actual)

Creatinine (mg/dl) Creat Clear (actual)  Actual  Estimated



Nursing Instructions

Prescribing Information: This Medication is associated with serious side effects including metabolic syndrome and diabetes. Please Consider an alternative.

Calculation Info

Nursing Precautions

Pharmacy Use Only: Dispensing Notes

Warning or Alert

# New Starts Checklist


- Rolled out October 2011 in the Department of Psychiatry
- Vice Chair must be consulted if the anti-psychotic is being prescribed for an off-label use
- Charts will be audited for compliance of New Starts Checklist
- Will be incorporated into EMR in 2012

# Where are we now?

\*24% of the initial population of PSYCKES patients have discontinued these medications


\*22% of the remaining patients are currently being tapered off the medications

**GNYHA PSYCKES Quality Collaborative 2011**  
**Maimonides Medical Center**  
Data Based on Initial PSYCKES Population (n=85)



# Antipsychotics Breakdown

(AOS - w/o Schizophrenia or Bipolar Disorder DX)



# Antipsychotics Breakdown

(WRP - Schizophrenia Diagnosis)

